
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

Rocheโs Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

GSK has announced positive results today from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China. These …

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its โResearching COVID to …

Hummingbird Bioscience has announced the initiation of two phase 1b clinical trials taking place in Australia. The trials will evaluate …

Australian precision microbiome company Microba has announced that the first participants in its phase 1 inflammatory bowel disease (IBD) clinical …

US clinical-stage biopharmaceutical company Kymera Therapeutics has shared newย data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …

Bellerophon Therapeutics has announced top-line results from its phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse for …

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …

Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine company, has announced positive topline …

Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, …

A new study has found that Ultraviolet C (UVC) emitting lamps are fast, effective, and safe at inactivating SARS-CoV-2, the …

Before any kind of new medicine can be made available to the market, it has to go through a strictly …

Serious diseases like COVID-19 put increasing pressure on researchers to find breakthrough treatments faster. Along with accelerated timelines, biopharma and …